Literatur
Hu R et al. Cancer Res. 2009;69(1):16–22.
Ryan CJ et al. N Engl J Med. 2013;368(2):138–148.
Beer TM et al. N Engl J Med. 2014;371(5):424–433.
Scher HI et al. N Engl J Med. 2012;367(13):1187–1197.
Ryan CJ et al. Lancet Oncol. 2015 Feb;16(2):152–160.
Azad AA et al. Clin Cancer Res. 2015;21(10):2315–2324.
Originalie
Antonarakis ES et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028–1038.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alsdorf, W., Bokemeyer, C. AR-V7 scheint prädiktiv für Resistenz gegen antiandrogene Therapie. Info Onkol. 18, 14–16 (2015). https://doi.org/10.1007/s15004-015-0933-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15004-015-0933-3